The present invention relates the use of certain cannabidiol derivatives and of their dimethyl heptyl homologs (CBD-DMH) in the treatment of nausea, in particular chemotherapy-induced nausea, and of anti-vomiting activity. The present invention relates also to the use of said cannabidiol derivatives being part of a pharmaceutical composition.
**FIG. 3**

**Mean ml saccharin solution consumed**

- **Vehicle**
  - Lithium: [Hatched area]
  - Saline: [Hatched area]

- **CBD**
  - Lithium: [Hatched area]
  - Saline: [Hatched area]

**CONDITIONING PRETREATMENT**

**FIG. 4**

**Mean ml saccharin solution consumed**

- **Vehicle**
  - Lithium: [Hatched area]
  - Saline: [Hatched area]

- **CBD-DMH**
  - Lithium: [Hatched area]
  - Saline: [Hatched area]

**CONDITIONING PRETREATMENT**
ANTI-NAUSEA AND ANTI-VOMITING ACTIVITY
OF CANNABIDIOL COMPOUNDS

BACKGROUND OF THE INVENTION

[0001] The present invention relates to the use of certain
cannabinoid derivatives and of their dimethyl heptyl
homologs (CBD-DMH) in the treatment of nausea and of
anti-vomiting activity.

[0002] It is known that cannabinoid compounds of general
formula I

\[
\begin{align*}
\text{R}^1 & \quad \text{OH} \\
\text{H} & \quad \text{R}^2
\end{align*}
\]

in which R' stands for CH₃, COOH or CH₂OH; and

[0004] R" stands for

[0005] a. straight or branched alkyl of 5 to 12
carbon atoms;

[0006] b. a group —O—R", where R" . . . . is a
straight or branched alkyl of 5 to 9 carbon atoms,
or a straight or branched alkyl substituted at the
terminal carbon atom by a phenyl group;

[0007] c. a group —(CH₂)n—0-alkyl, where n is
an integer from 1 to 7 and the alkyl group contains
1 to 5 carbon atoms, are anti-inflammatory agents
and have analgesic, antianxiety, anticonvulsive,
neuroprotective, antipsychotic and anticancer
activity.

[0008] There are known many compounds being present
in marihuana which have anti-nausea and anti-vomiting
activity. However, many of them are psychoactive which is
undesired for this purpose.

SUMMARY OF THE INVENTION

[0009] It has now been found that cannabinoid compounds
of general formula I are not psychoactive but are very useful
in the treatment of nausea and of anti-vomiting activity.

[0010] The present invention thus consists in the use of
cannabinoid compounds of general formula I in the treatment
of nausea and of vomiting activity. The compounds are used
in particular in the treatment of chemotherapy-induced nau-
sea.

[0011] Thus the invention provides methods for treating
nausea and/or vomiting by administering to a subject in need
of such treatment a cannabinoid compound as described
herein. As used herein, a "subject" shall mean a human, a
vertebrate mammal including but not limited to a dog, cat,
horse, cow, pig, sheep, goat, or non-human primate, e.g.,
monkey, or a fowl, e.g., chicken. Included within the scope
of the present invention are all animals which are susceptible
to nausea and/or vomiting. The term "effective amount" of
a cannabinoid compound (optionally combined with other
non-cannabinoid compounds) refers to the amount necessary
or sufficient to realize a desired biologic effect, e.g., a
lessening of nausea and/or vomiting activity.

[0012] The cannabinoid compound of formula II and/or its
DMH homolog of formula III may be used as such. It may
also be used as part of a pharmaceutical preparation being
selected among a tablet, a capsule, a granule, a suspension
in a solution, etc.

[0013] Said pharmaceutical preparation may comprise in
addition to the active ingredient an excipient selected among
a carrier, a disintegrant, a lubricant, a stabilizer, a flavoring
agent, a diluent, another pharmaceutically effective
compound, etc.

[0014] The diluent may be an aqueous cosolvent solution
comprising a pharmaceutically acceptable cosolvent, a
micellar solution prepared with natural or synthetic ionic or
nonionic surfactants, or a combination of such cosolvent and
micellar solutions, etc.

[0015] The carrier may consist essentially of a solution of
ethanol, a surfactant or water, or essentially of an emulsion
comprising triglycerides, lecitin, glycerol, an emulsifier, an
antioxidant, water, etc.

[0016] The present invention will hereinafter be described
in detail without being limited by said description.

BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The Figures illustrate the following reactions:

[0018] FIG. 1. Mean (+SEM) frequency of conditioned
rejection reactions elicited by a lithium- or saline-paired
saccharin solution in Experiment 1 when rats were tested 30
min after an injection of vehicle or cannabinoid (CBD). The
groups varied on the basis of the pretreatment drug (CBD or
Vehicle) administered 30 min prior to an intraoral infusion
of saccharin solution during the conditioning trial and the
conditioning drug (Lithium or Saline) administered follow-
ing saccharin exposure.

[0019] FIG. 2. Mean (+SEM) frequency of conditioned
rejection reactions elicited by a lithium- or saline-paired
saccharin solution in Experiment 2 when the pretreatment
and test drug was cannabinol dimethylheptyl (CBD-
DMH).

[0020] FIG. 3. Mean (+SEM) ml consumed of lithium-
paired or saline-paired saccharin solution during a 6 hr
consumption test on the day following the final taste reac-
tivity (TR) test trial among rats pretreated with 5 mg/kg of
CBD or Vehicle prior to the conditioning trial in Experiment
1.

[0021] FIG. 4. Mean (+SEM) ml consumed of lithium-
paired or saline-paired saccharin solution during a 6 hr
consumption test on the day following the final TR test trial
among rats pretreated with 5 mg/kg of CBD-DMH or
Vehicle prior to the conditioning trial in Experiment 2.
DETAILED DESCRIPTION OF THE INVENTION

[0022] 1) Materials and Methods

[0023] a. Experiment 1 uses cannabinoid (CBD) of formula II:

[0024] Experiment 2 uses cannabinoid-dimethyl heptyl (CBD-DMH) of formula III:

[0025] Experiment 1 were used 29 male rats and in Experiment 2 were used 24 male Sprague-Dawley rats (Charles River Labs, St. Constant, Quebec), which weighed 290-350 gm on the conditioning day. They were individually housed in stainless steel hanging cages in a colony room kept at 21°C, on a 12:12 hr light/dark schedule with the lights on at 07:00 h. Throughout the experiment, the rats were maintained on ad-lib Purina Rat Chow and water. The procedures were approved by the Wilfrid Laurier University Animal Care Committee according to the guidelines of the Canadian Council on Animal Care.

[0026] b. The rats were surgically implanted with introral cannulae as described by Parker, L.A. Learn Motiv., 13, 281-303 (1982). The surgical anesthesia preparation included administration of 0.4 mg/kg atropine solution i.p. 15 min prior to ketamine (75 mg/kg, i.p.) combined with xylazine (10 mg/kg, i.p.) which was dissolved in sterile water and administered at a volume of 1 ml/kg. On each of three subsequent days during recovery from surgery, the cannulae were flushed with a chlorohexidine rinse (Novlosan; 0.1% chlorohexidine) to prevent infection.

[0027] c. The design of the experiments evaluated the effect of CBD (Experiment 1) and of CBD-DMH (Experiment 2) on the establishment of conditioned rejection reactions, on the expression of conditioned rejection reactions during testing and the potential role of state dependent learning decrements in responding. The rats were randomly assigned to independent groups on the basis of the pretreatment drug and the conditioning drug. In Experiment 1, the groups were as follows: CBD-lithium (n=6), CBD-saline (n=6), Vehicle-lithium (n=6), Vehicle-saline (n=6). All rats were administered two test trials, one following an injection of the drug (Experiment 1: CBD; Experiment 2: CBD-DMH) and the other following an injection of the vehicle. C6H5. The order of the test trials was counterbalanced among the rats in each group.

[0028] d. CBD and CBD-DMH were prepared in a mixture (2.5 mg/ml Vehicle) of 1 ml alcohol/1 ml emulsifier/18 ml saline and were administered at a volume of 2 ml/kg. Lithium chloride was prepared in a 0.15 M (wt/vol) solution with sterile water and was administered at a volume of 20 ml/kg. All injections were intraperitoneally (ip) administered.

[0029] e. One week following the surgery, the rats were adapted to the conditioning procedure. On the adaptation trial, each rat was transported into the room that contained the Plexiglass test chamber (25 cm x 25 cm x 12 cm). The room was illuminated by four 25-W light bulbs located 30 cm from either side of the chamber. Each rat was placed individually into the test chamber, and a 30-cm infusion hose was then connected to the cannula through the ceiling of the chamber. A syringe was connected to the hose and placed into the holder for the infusion pump (Model 22; Harvard Apparatus, South Natick, Mass.). After 60 s, the pump delivered water through the tube into the rat’s mouth at the rate of 1 ml/min for 2 min. The rat was then returned to its home cage.

[0030] f. The conditioning trial occurred on the following day; it was identical to the adaptation trial, except that the rats were infused with 0.1% saccharin solution rather than water. Thirty min prior to the conditioning trial, the rats were injected ip with either 2 ml/kg of the drug (CBD: Experiment 1; CBD-DMH: Experiment 2) or with the vehicle in which the drug was mixed. Immediately following the infusion of saccharin solution, the rats were injected ip with 20 ml/kg of lithium chloride or saline. During the intraoral infusion, the oro-facial and somatic responses displayed by the rats were videotaped from a mirror mounted at a 45° angle beneath the test chamber. Immediately following the TR test, the rat was returned to its home cage.

[0031] g. The Taste Reactivity (TR) test trials were administered 4 and 6 days after the conditioning trial; on the day prior to the first test trial, the rats received an adaptation trial as described above. On each of two test trials, the rats were injected with either 5 mg/kg of the test drug (CBD: Experiment 1; CBD-DMH: Experiment 2) or with the vehicle, thirty min prior to receiving an infusion of saccharin solution for 2 min at the rate of 1 ml/min. The order of the tests was counterbalanced among the rats within each group. The oro-facial and somatic reactions displayed by the rats were videotaped during the saccharin exposure.

[0032] h. In both experiments, on the day following the final TR test trial, the rats were administered a consumption test trial in a non-deprived state. On this trial, the water bottles were replaced with tubes containing the saccharin solution and the amounts consumed over a 6 hr period of drinking were recorded.

[0033] i. Taste reactivity scoring: A rater blind to the experimental conditions scored the videotapes on two occasions in slow motion (½ speed) using the Observer (Noldus, NL) event-recording program on a PC computer. The frequency of the rejection reactions of gaping (rapid large amplitude opening of the mandible with retraction of the
corners of the mouth), chin rubbing (mouth or chin in direct contact with the floor or wall of the chamber and body projected forward) and paw treads (sequential extension of one forelimb against the floor or wall of the chamber while the other forepaw is being retracted) were summed to provide a rejection reaction score (inter-rater reliability: [0034] Experiment 1: Vehicle test r (29)=0.91, CBD test r (29)=0.90; Experiment 2: Vehicle test r(24)=0.95; CBD-DMH test r (24)=0.97.

[0035] 2) Results

[0036] a. Taste Reactivity Test:

[0037] FIGS. 1 and 2 present as indicated above the mean frequency of rejection reactions displayed by the rats in the various groups during the vehicle test trial and during the drug (CBD: Experiment 1, CBD-DMH: Experiment 2) test trial. In both experiments, the pattern of responding indicates that the cannabinoid drug interfered with both the establishment of conditioned rejection and with the expression of previously established conditioned rejection reactions.

[0038] In Experiment 1 with CBD, the 2 by 2 by 2 mixed factor ANOVA revealed significant effects of pretreatment drug, F(1, 25)=6.6; p=0.022, conditioning drug, F (1, 25)=10.9; p=0.003, test drug, F (1, 25)=7.4; p=0.012, test drug by conditioning drug, F(1, 25)=6.0; p=0.021 and a pretreatment by conditioning drug interaction that approached statistical significance F(1, 25)=3.6; p=0.069. Subsequent Least Significant Difference (LSD) post-hoc pair-wise comparison tests [20] revealed that the lithium-conditioned rats, but not the saline-conditioned rats, displayed significantly fewer conditioned rejection reactions during the CBD test trial than during the vehicle test trial (p’s<0.05). This indicates that CBD attenuated the expression of previously established conditioned rejection reactions. Additionally, across both test drug conditions, the lithium-conditioned rats pretreated with CBD displayed fewer rejection reactions than those pretreated with vehicle (p<0.05) indicating that the CBD pretreatment during conditioning attenuated the establishment of conditioned rejection reactions, presumably by interfering with lithium-induced nausea.

[0039] In Experiment 2, with CBD-DMH, the 2 by 2 by 2 mixed factors ANOVA revealed a significant effect of test drug, F (1, 20)=4.6; p=0.044 and a significant pretreatment drug by conditioning drug by test drug interaction, F (1, 20)=5.6; p=0.028. Subsequent LSD post-hoc pair-wise comparison tests revealed that Group Vehicle-Lithium displayed significantly more rejection reactions during the vehicle test than any other group (p’s<0.01) and that this group displayed more rejection reactions during the vehicle test than during the drug test (p<0.01). CBD-DMH interfered with the establishment of conditioned rejection reactions when administered prior to a saccharin-lithium pairing and with the expression of these conditioning rejection reactions when administered prior to the subsequent test of conditioning.

[0040] The attenuation of lithium-induced conditioned rejection reactions during conditioning or testing cannot be interpreted as state-dependent learning decrement, because when rats were trained and tested in the same cannabinoid state, they displayed fewer rejection reactions than when they were trained and tested in the same vehicle state.

[0041] b. Consumption Test:

[0042] FIGS. 3 and 4 present the mean ml of saccharin solution consumed by the various groups in Experiments 1 and 2 respectively. As is apparent, rats suppressed their consumption of a lithium-paired saccharin solution, but pretreatment with CBD (Experiment 1) or CBD-DMH (Experiment 2) prior to conditioning did not modulate the strength of the avoidance response. A 2 by 2 ANOVA for each Experiment revealed only a significant effect of conditioning drug for Experiment 1 (F[1,22]=25.01; p<0.001) and a marginally significant effect of conditioning drug for Experiment 2 (F[1, 19]=4.36; p=0.051). There were no other significant effects.

[0043] 3) Interpretation

[0044] The non-psychoactive cannabinoids, CBD and CBD-DMH, interfered with the establishment of conditioned rejection reactions (presumably by reducing the lithium-induced nausea) and with the expression of previously established conditioned rejection reactions (presumably by reducing conditioned nausea during test). These results are the first to describe the anti-nausea properties of the naturally occurring cannabinoid, found in marijuana and its dimethylheptyl homolog. It has previously been reported similar effects produced by the 5HT3 antagonist anti-emetic agent, ondansetron, and THC; that is, both agents interfered with the establishment and the expression of conditioned rejection reactions in rats. As has previously been reported using the antiemetic agent, ondansetron, as the pretreatment agent, CBD and CBD-DMH pretreatment did not interfere with the establishment of conditioned taste avoidance in a consumption test. Since treatments without emetic properties elicit taste avoidance, but not conditioned rejection reactions, taste avoidance does not reflect conditioned sickness. On the other hand, only treatments with emetic effects produce conditioned rejection reactions in rats suggesting that this affective change in taste palatability is mediated by nausea. The anti-emetic effects of cannabinoid agonists, such as THC and WIN 55-212, appear to be mediated by specific actions at the CB1 receptor, because these effects are blocked by administration of the CB1 receptor antagonist, SR-141716. On the other hand, CBD and CBD-DMH have relatively weak affinity for the CB1 receptor and may be act by preventing the uptake of the endogenous cannabinoid agonist, anandamide. Further research is necessary to determine the specific mechanism by which CBD and CBD-DMH prevent nausea in rats.

[0045] 4) Conclusion

[0046] The above results demonstrate that the non-psychoactive component of marijuana, cannabidiol, and its synthetic analog, cannabidiol dimethylheptyl, interfere with nausea and with conditioned nausea in rats.

[0047] Therapeutically effective amounts of cannabidiol compounds and homologs can be determined from animal models as described above and as will be well known to and routinely performed by one of ordinary skill in the art. The applied dose can be adjusted based on the relative bioavailability and potency of the administered compound. Adjusting the dose to achieve maximal efficacy based on the methods described above and other methods as are well-known in the art is well within the capabilities of the ordinarily skilled artisan.
What is claimed is:

1. A method for the treatment of nausea and of vomiting, comprising administering to a subject an effective amount of a cannabidiol compound of general formula I.

2. The method of claim 1, wherein the cannabidiol compound is used in particular in the treatment of chemotherapy-induced nausea.

3. The method of claim 1, wherein the cannabidiol compound is a compound of formula II.

4. The method of claim 3, wherein the cannabidiol compound is used in particular in the treatment of chemotherapy-induced nausea.

5. The method of claim 1, wherein the cannabidiol compound is a cannabidiol homolog of formula III.

6. The method of claim 5, wherein the cannabidiol compound is used in particular in the treatment of chemotherapy-induced nausea.

7. The method of claim 1, wherein the cannabidiol compound of formula I is part of a pharmaceutical preparation being selected from the group consisting of a tablet, a capsule, a granule, and a suspension in a solution.

8. The method of claim 7, wherein said pharmaceutical compound comprises in addition to the active ingredient an excipient selected from the group consisting of a carrier, a disintegrant, a lubricant, a stabilizer, a flavoring agent, a diluent, and another pharmaceutically effective compound.

9. The method of claim 8, wherein the diluent is an aqueous cosolvent solution comprising a pharmaceutically acceptable cosolvent, a micellar solution prepared with natural or synthetic ionic or nonionic surfactants, or a combination of such cosolvent and micellar solutions.

10. The method of claim 3, wherein the cannabidiol compound of formula II is part of a pharmaceutical preparation being selected from the group consisting of a tablet, a capsule, a granule, and a suspension in a solution.

11. The method of claim 10, wherein said pharmaceutical compound comprises in addition to the active ingredient an excipient selected from the group consisting of a carrier, a disintegrant, a lubricant, a stabilizer, a flavoring agent, a diluent, and another pharmaceutically effective compound.

12. The method of claim 11, wherein the diluent is an aqueous cosolvent solution comprising a pharmaceutically acceptable cosolvent, a micellar solution prepared with natural or synthetic ionic or nonionic surfactants, or a combination of such cosolvent and micellar solutions.

13. The method of claim 3, wherein the cannabidiol homolog of formula III is part of a pharmaceutical preparation being selected from the group consisting of a tablet, a capsule, a granule, and a suspension in a solution.

14. The method of claim 13, wherein said pharmaceutical compound comprises in addition to the active ingredient an excipient selected from the group consisting of a carrier, a disintegrant, a lubricant, a stabilizer, a flavoring agent, a diluent, and another pharmaceutically effective compound.

15. The method of claim 14, wherein the diluent is an aqueous cosolvent solution comprising a pharmaceutically acceptable cosolvent, a micellar solution prepared with natural or synthetic ionic or nonionic surfactants, or a combination of such cosolvent and micellar solutions.